103 results about "Fibroblastic cell" patented technology

Provided are immortalized fish fibroblast cells and food products comprising said fish fibroblast cells.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The invention provides a polylactic acid-polycitrate composite microsphere as well as a preparation method and application thereof. The polylactic acid-polycitrate composite microsphere is prepared from the following raw materials: a polycitrate prepolymer and poly-L-lactic acid. According to the polylactic acid-polycitrate composite microsphere provided by the invention, the polycitrate prepolymer is introduced, so that mechanical-degradation double-phase matching of a material can be realized, the hydrophobicity of the poly-L-lactic acid can be reduced, the hydrophilic-hydrophobic balance of the surface of the composite microsphere is realized, the affinity and biological activity of cells are improved, and the biocompatibility of the composite microsphere is improved. And the poly citrate prepolymer and the poly-L-lactic acid are matched for use, so that the whole polylactic acid-poly citrate composite microsphere has bionic viscoelasticity, thereby promoting the spreading of fibroblasts and the secretion of more integrin and collagen monomers, facilitating the behavior regulation and control of cells, and mildly stimulating the regeneration of collagen.

The invention discloses a method for enhancing mechanical force of CAR-T cells on target cells to overcome mechanical immune checkpoints of SFs and application, and relates to the technical field of crossing of immunotherapy and biomechanics, in particular to CAR-T cells targeting fibroblast activated protein. The invention discloses a CAR-T (chimeric antigen receptor T-T) cell and SFs (small-form-factor s) DNA (deoxyribonucleic acid) nano connector for connecting the CAR-T cell with the SFs, the formation of a CAR cluster and mechanical force transmission are promoted by shortening the membrane spacing of an immune synaptic interface to 16-28nm, the DNA nano connector is formed by self-assembling complementary tetrahedral DNA structures, and the TDS comprises a single-stranded DNA vertex S4 with the length of 24-58 nucleotides. According to the method for enhancing the mechanical force of the CAR-T cells on the target cells to overcome the mechanical immune checkpoints of the SFs and the application, the escape and killing problems of the soft target cells are solved, the soft target cells are efficiently removed, and the killing rate of the CAR-T cells treated by DNJ-17 on the SFs is remarkably increased.

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.

The invention relates to an estrogen receptor alpha and fibroblast activating protein dual-targeting near-infrared fluorescent probe as well as a preparation method and medical application thereof. Specifically, the probe can be used as a fluorescence probe for developing cells co-expressing the estrogen receptor alpha and the fibroblast activating protein, and can also be used as a near-infrared fluorescence imaging probe for diagnosing benign / malignant lesions such as nodules / tumors co-expressing the estrogen receptor alpha and the fibroblast activating protein. The fluorescent probe can also be applied to research on related biological events in cells for co-expressing the estrogen receptor alpha and the fibroblast activating protein, and particularly can be applied to fluorescent navigation in tumor resection operations for co-expressing the estrogen receptor alpha and the fibroblast activating protein; particularly, the composition can be applied to the synergistic treatment of an anti-estrogen therapy and a photodynamic therapy on a diseased region which co-expresses the estrogen receptor alpha and the fibroblast activating protein.

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.

The invention provides a gene editing cell and a method for producing extremely high molecular weight hyaluronic acid by using the cell. The preparation method comprises the following steps: by taking PUC57 as a skeleton carrier, constructing a recombinant plasmid containing an HAS2 gene, and transfecting a mole NMRHas2 gene, a chicken CHICKHAS2 gene, an astronomy mouse SNMHAS2 gene, a dakalimeris mouse DMRHAS2 gene or a mole mouse BMRHAS2 gene into chicken fibroblasts through lipidosome to construct a stably transfected cell line, so that hyaluronic acid with extremely high molecular weight can be stably obtained. The method provided by the invention overcomes the defects of non-uniform molecular weight distribution of HA product sources, low molecular weight and single method in the prior art, and has important significance for developing medicines for treating osteoarthritis and novel medical equipment products.

The invention relates to the technical field of cosmetics, in particular to a compound active peptide with functions of resisting aging and whitening skin and application of the compound active peptide. Comprising acetyl hexapeptide-1, nonapeptide-1, acetyl tetrapeptide-11, hexapeptide-9 and palmitoyl hexapeptide-12. The compound peptide disclosed by the invention can play a synergistic anti-aging and whitening role on an epidermal layer and a corium layer, and has multiple advantages; the compound peptide acts on epidermal layer keratinocytes, dermal layer fibroblasts and B16F10 cells, and can be used for detecting the senescence of the cells by influencing the expression quantity of cell senescence marker genes, influencing the cell cycle, influencing the expression quantity of extracellular matrix related proteins, influencing melanin synthesis and influencing the secretion quantity of acetylcholine in the cells. Multiple skin anti-aging and whitening effects synergistically exerted on the epidermal layer and the corium layer are achieved.

The present application relates to a kind of human gastric cancer primary fibroblast separation culture and purification method and its application.The human gastric cancer primary fibroblast separation culture and purification method provided by the present application are simple, efficient.The separation culture method and the purification method provided by the present application can complete tissue dissociation in shorter time, and cooperate multiple immunomagnetic beads to remove miscellaneous cells, so that the gastric cancer primary fibroblast group of stable, relatively consistent morphology adherent growth is obtained, phenotype observation is facilitated, and the interference of miscellaneous cells to subsequent function experiment is reduced.Enriched cells are expanded after culture, and can be used for the subtype research of fibroblast, microtumor environment related function experiment.

Methods and compositions relating to the treatment of degenerative disc disease are provided.SOLUTION: In some embodiments, cannabidiol is utilized to enhance the therapeutic and / or regenerative activity of fibroblasts. In other embodiments, cannabidiol is utilized to augment the reparative effects of other regenerative cells, including monocytes, mesenchymal stem cells, and / or hematopoietic stem cells. In some embodiments, cannabidiol is utilized in the culture media of regenerative cells prior to administration of said cells.SELECTED DRAWING: Figure 1

The application discloses application of miR-30a-5p in preparation of a product for treating airway stenosis. The application finds that miR-30a-5p plays an important regulatory role between airway basal stem cells and airway fibroblasts, and through the carrying of extracellular vesicles, miR-30a-5p is transmitted from the airway basal stem cells to the airway fibroblasts, targets and regulates the expression of a key gene FAP, inhibits the activation of the airway fibroblasts, reduces the collagen gel contraction ability of the airway fibroblasts, improves the extracellular matrix remodeling of the airway fibroblasts, can effectively stabilize the tracheal granulation tissue, prevents the recurrence of airway stenosis, and has application value for treating airway stenosis.

The invention discloses a peptide with an anti-photoaging effect as well as a preparation method and application of the peptide. The cyclic dipeptide cyclo (LO) and the linear dipeptide LO disclosed by the invention can be used for remarkably inhibiting the activity of MMP-1 and efficiently blocking collagen degradation. In addition, the cyclic dipeptide and the linear dipeptide have no cytotoxic effect when being co-cultured with fibroblasts, so that the cyclic dipeptide and the linear dipeptide have no stimulation and side effects on cells, and are high in safety and good in stability. The cyclic dipeptide and the linear dipeptide disclosed by the invention can resist UVA (Ultraviolet A) damage, have a promoting effect on cell proliferation activity after UVA irradiation and have an anti-aging effect on cells after UVA irradiation. The two peptides disclosed by the invention can be used for preparing medicines or cosmetics for resisting light aging, resisting aging, beautifying and protecting skin. The peptide fragment disclosed by the invention has a good application prospect in the fields of medicines, cosmetics and the like.

The subject invention pertains to a novel method for treating Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential oftype 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This present invention aims at enhancing the muscle regeneration and revascularization for obese and diabetes individuals.

The present invention is directed to a method for identifying i) metastatic potential of a cancer cell sample from a non-metastatic cancer or ii) potential for malignant alterations in a healthy cell, the method comprising the steps of: a) culturing a cancer cell sample from a non- metastatic cancer or a healthy cell sample in a composition comprising cancer-associated fibroblasts, CAFs, preferably in two-dimensional or three-dimensional cell culturing conditions; and b) monitoring morphological alterations in the sample cells during and / or after the culturing step a), and / or determining the expression level of biomarkers relating to metastasis in the sample cells during and / or after the culturing step a); wherein the sample cells which show morphological alterations relating to metastasis and / or changes in the expression levels of said biomarkers in comparison to the levels of said biomarkers measured from corresponding samples cultured in a composition comprising normal fibroblasts, NFs, are identified as having metastatic potential or potential for malignant alterations. The present invention is also directed to a system for culturing eukaryotic cells comprising a solid surface comprising at least one partition suitable for culturing eukaryotic cells, wherein said at least one partition contains a combined cell culture comprising i) cancer cells from a non- metastatic cancer or healthy cells and ii) cancer-associated fibroblasts, CAFs, wherein said partition is a well or chamber.

The invention relates to the field of cell culture. The invention particularly relates to culturing cells, such as fibroblasts, to obtain collagen sheets. Modified scaffolds have been found to improve the characteristics of the method. The invention also relates to a collagen sheet and to leather obtained by tanning such a collagen sheet.

The invention belongs to the technical field of biology, and discloses a serum-free culture medium and application thereof in obtaining nerve cells through embryo fibroblast transdifferentiation. The serum-free culture medium consists of a basic culture medium, a protein additive and cell culture auxiliary components, the protein additive consists of transferrin, a leukemia inhibition factor and a basic fibroblast growth factor; the final concentration of the transferrin is 5 ng / mL-30 ng / mL, the final concentration of the leukemia inhibition factor is 50 ng / mL-150 ng / mL, and the final concentration of the basic fibroblast growth factor is 10 ng / mL-25 ng / mL. The serum-free culture medium can promote the conversion speed of transdifferentiation of fibroblasts into nerve cells, can significantly improve the transdifferentiation efficiency, and can improve the cell survival rate of transdifferentiation of mouse embryo fibroblasts into nerve cells.

The invention relates to the technical field of biomedicine, in particular to a method for identifying fibroblast subsets in colorectal cancer tissue based on single cell sequencing, and provides a method for identifying fibroblast subsets in colorectal cancer tissue based on single cell sequencing. The method comprises the following steps: S1, extracting colorectal cancer tissues: obtaining tumor tissues removed from the colorectal cancer tissues, and collecting a suspension to prepare a single-cell suspension; s2, single cell sequencing analysis: constructing a high-throughput sequencing library; s3, data analysis: processing the sequencing data by using a CellRanger software pipeline, and mapping readings to a genome and a transcriptome; and carrying out data dimension reduction and visualization. S4, identification of the tumor-associated fibroblast subpopulation: after the total cell type in the colorectal cancer tumor tissue is identified, annotating the cells; and identifying differentially expressed genes by using a Seurt software package, and carrying out function enrichment analysis, so as to identify various cell types.

The application relates to the technical field of biomaterials, and particularly discloses a PHA combined microsphere as well as a preparation method and application thereof. The PHA combined microsphere provided by the application contains 10-40 wt% of PHA microspheres with a weight average molecular weight of less than 30000 Da and 1-40 wt% of PHA microspheres with a weight average molecular weight of more than 100000 Da, with the PHA being selected from one or more of poly-beta-hydroxybutyric acid, a copolymer of 3-hydroxybutyric acid ester and 3-hydroxyvaleric acid ester, a copolyester of 3-hydroxybutyric acid and 3-hydroxyhexanoic acid and poly(3-hydroxybutyric acid-co-4-hydroxybutyric acid). After the PHA combined microsphere is filled in the skin, on one hand, the PHA combined microsphere can be rapidly degraded in an early stage and promote the reproduction of fibroblasts and endothelial cells in a short time; on the other hand, the PHA combined microsphere can be continuously degraded within 21 weeks and cannot cause inflammation, so that the effect of persistent filling is achieved.

The invention discloses a patient-specific bile duct cancer chip and a method thereof in dynamic drug resistance evolution analysis, and relates to the technical field of biomedicine, the patient-specific bile duct cancer chip comprises a central tumor microenvironment chamber, the central tumor microenvironment chamber is internally provided with a plurality of independent three-dimensional culture chambers, and patient-derived cells are embedded and loaded in a matrix; the perfusion channel network is connected with the plurality of three-dimensional culture chambers to form a flow channel and is used for continuously perfusing a culture medium, a medicine or a stromal cell suspension and simulating blood flow and interstitial fluid flow, and the microenvironment regulation and control unit is integrated with the perfusion channel network to control the flow channel. The chip provided by the invention integrates tumor cells, cancer-related fibroblasts and endothelial cells, so that the tumor cells, the cancer-related fibroblasts and the endothelial cells grow in a 3D matrix to form organoids with spatial structures and interstitial infiltration, and the microfluidic perfusion simulates blood / interstitial fluid flow, so that the drug test environment is closer to the actual situation of a human body, and the obtained data has higher physiological prediction value.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

The present invention relates to the field of cell therapy. Disclosed are a fibroblast activation protein-targeting CAR T-cell, a preparation method therefor, and an application thereof. A CAR T-cell can be prepared by introducing an FAP-targeting chimeric antigen receptor (CAR) into a T lymphocyte, wherein the CAR in the CAR T-cell comprises a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling region, and a CD3 signaling domain. The CAR T-cell specifically recognizes the FAP by means of a single-chain variable fragment (scFv), which activates an intracellular signaling pathway, releasing cytokine IFN-γ, and exhibiting a cytotoxic effect on FAP+ cells, thereby achieving specific depletion of FAP+ cells at a lesion site. The CAR-T cell can be used for treating diseases characterized by upregulated FAP expression, such as fibrosis (pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, etc.), arthritis, autoimmune disorders (Crohn's disease, rheumatoid arthritis, etc.), and cardiovascular diseases, and demonstrates tremendous application potential and commercial value.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a benzenesulfonic acid or benzenesulfonic acid derivative-guanidine eutectic crystal as well as a preparation method and application thereof. The benzenesulfonic acid or benzenesulfonic acid derivative-guanidine eutectic is a benzenesulfonic acid or benzenesulfonic acid derivative and guanidine eutectic, and the molar ratio of benzenesulfonic acid or benzenesulfonic acid derivative to guanidine is 1: (1-2). According to the invention, a proper benzenesulfonic acid derivative is screened and is taken as a ligand to be combined with guanidine, so that a series of benzenesulfonic acid or benzenesulfonic acid derivative-guanidine eutectic crystals are successfully synthesized. The eutectic can promote proliferation and migration of fibroblasts, vascular endothelial cells and keratinocytes in skin, reduce apoptosis of skin peripheral nerves and promote growth of axons so as to realize rapid healing of diabetic wounds. Meanwhile, after benzenesulfonic acid and derivatives thereof form eutectic crystals with guanidine, slow release of guanidine ions can be realized, and potential toxicity of guanidine is reduced while the drug effect is improved.

This invention proposes a nucleic acid aptamer that specifically binds to human senescent dermal fibroblasts (HDFs), along with its screening, identification, and application. Specific aptamers exhibiting high targeting specificity to human senescent HDFs were screened using Cell-SELEX technology. The three selected candidate aptamers showed binding rates of 57.5%, 86.2%, and 50.7% to senescent HDF cells within the same timeframe, respectively, demonstrating high specificity and targeted binding ability. Furthermore, the aptamer possesses potential for detecting, imaging, and regulating the function of senescent cells, successfully providing a new direction for targeted anti-aging interventions and therapeutic applications.

The application provides a culture medium for producing dendrobium stem cell exovesicles and an application thereof, relates to the technical field of biology, and the culture medium for producing dendrobium stem cell exovesicles comprises 0.1-0.5 mg / L naphthalene acetic acid, 0.05-0.2 mg / L thidiazuron, 0.5-5 muM sodium selenate and 1-10 mg / L glutathione. The culture medium for producing dendrobium stem cell exovesicles and the method for preparing dendrobium stem cell exovesicles by using the culture medium for producing dendrobium stem cell exovesicles provided by the application have made significant progress in the yield and quality of dendrobium stem cell exovesicles. Meanwhile, the prepared dendrobium stem cell exovesicles have significant DPPH free radical scavenging capacity and improve the healing capacity of skin fibroblasts.

The invention discloses a pharmaceutical composition for inhibiting tumor drug resistance and application thereof. The pharmaceutical composition comprises an exosome inhibitor, nintedanib and gemcitabine, the exosome inhibitor, the nintedanib and the gemcitabine are used in a combined manner, so that the cell viability of the CTS can be remarkably reduced, and the proportion of apoptotic cells in the CTS can be remarkably increased; the pharmaceutical composition interferes with the mutual transformation process between normal fibroblasts and CAFs, and inhibits secretion and release of EVs and reduces formation of new CAFs while restoring the CAFs existing in TME to normal fibroblasts, thereby successfully reversing the drug resistance of tumors.

Compositions and methods including stromal cells that have been genetically engineered to knock down or silence one or more genes are disclosed herein. The compositions include a population of isolated stromal cells that have been genetically engineered to reduce or eliminate expression one or more genes which confers permissivity to invasion (referred to herein as INVGOI) in fibroblasts, or cancer associated fibroblasts (CAFs). The cell compositions can be administered to a subject in need thereof to reduce or eliminate expression of one or more genes which confer permissivity to cancer invasion. Alternatively, inhibitory functional nucleic acids which specifically target one or more INV-GOI can be administered to a subject to treat cancer and in additional to chemotherapy, to sensitize cancer cells to chemotherapy.

The invention belongs to the technical field of biology, and particularly relates to a CFTSR gene, a CFTSR gene simulant and application of the CFTSR gene simulant. The nucleic acid sequence of the CFTSR gene is as shown in SEO ID NO. 1. The nucleic acid sequence of the CFTSR gene simulant is as shown in SEO ID NO. 2. The CFTSR gene provided by the invention can be used as a marker for fibroblast activation, and is used for a kit for detecting cardiac fibroblast activation. The CFTSR gene simulant can be used as a therapeutic drug for myocardial infarction injury, and the overexpression of the CFTSR gene can significantly inhibit the proliferation of fibroblasts and activate the repair of damaged myocardial tissues. Based on CFTSR mimics, a simulant of the CFTSR gene is constructed, and the simulant can be conveyed to the position of a heart lesion and can be used as a medicine for treating myocardial infarction injury, so that effective treatment of the lesion is realized.

The invention discloses an FGF2 inhibitor composition of a targeted iCAFs subgroup and application of the FGF2 inhibitor composition in bladder cancer prevention and treatment, and relates to the technical field of FGF2 inhibitor compositions of targeted iCAFs subgroups, the FGF2 inhibitor composition is used for preparing a medicine for bladder cancer prevention and treatment, the composition comprises an FGF2 inhibitor, and the FGF2 inhibitor can inhibit the bladder cancer by inhibiting interaction between FGF2 secreted by ICAM1 + iCAFs and tumor stem cell surface CD44, so that the bladder cancer can be prevented and treated, and the bladder cancer can be prevented and treated. According to the application disclosed by the invention, ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation in a bladder cancer recurrence related tumor microenvironment is targeted, a fibroblast growth factor FGF2 signal secreted by the ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation is specifically inhibited, the dependency support of the tumor microenvironment on the stemness maintenance of the tumor stem cells is destroyed, and the stemness maintenance of the recurrence related tumor stem cell subpopulation is inhibited. Therefore, the biological basis of tumor recurrence and progression is weakened from the source.

The application provides a method for transdifferentiation of fibroblasts into hair papilla-like cells and application thereof, and relates to the technical field of biotechnology. The transdifferentiation method comprises inducing fibroblasts by using Peficitinib, so that the fibroblasts are transdifferentiated into hair papilla-like cells. A large number of hair papilla-like cells with hair induction capacity can be obtained in vitro by the method, and the problem that primary separated hair papilla cells are insufficient for developing alternative therapies for treating alopecia in the prior art is solved.